News

The first patient has been dosed in the first phase IIa trial, which is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profile of an intravenous formulation

Chronic idiopathic thrombocytopenic purpura (ITP) is a condition characterized by increased autoimmune platelet destruction and inadequate platelet production. The primary objective of the study is to evaluate the

Previously, the company had rejected the idea of an acquisition as it wanted to continue with its intended business plan. MedImmune commented that some of its shareholders have

In December 2003, Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-886, for co-development and commercialization with AstraZeneca. The collaboration included development of

The phase II trial was conducted to assess safety, pharmacodynamics and pharmacokinetics of Hematide in hemodialysis patients with stable baseline hemoglobin (Hgb) levels between 10 and 12.5 g/dL

The reformulation of Suprax allows parents to administer fewer teaspoons per dose of the antibiotic to their children. When using the novel dose, parents would need to administer

The first phase III study demonstrated a statistically significant achievement of all primary and secondary endpoints. Additionally, all primary and secondary endpoints were achieved with statistical significance in

The company initially planned to report first quarter earnings on April 19 but has postponed the announcement to incorporate results of the Aranesp study in small cell lung

Researchers at UT Southwestern Medical Center used a quick-screen technology to isolate 87 genes that seem to affect how sensitive human cancer cells are to certain chemotherapy drugs.